NCT07927478
Transcutaneous Auricular Vagal Neuromodulation Therapy (AVNT™) in Chronic Kidney Disease Autonomic Dysfunction
StatusNot Yet Recruiting
PhaseNot applicable
SponsorNYU Langone Health
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in Orthostatic Heart Rate Response
Timeframe: Week 0, Week 2
Secondary (6)
Change in high-sensitivity C-reactive protein (hs-CRP) (pg/mL)
Change in Interleukin-6 (IL-6) (pg/mL)
Change in Urine Albumin-Creatinine Ratio (UACR) (mg/g creatinine)
Change in Composite Autonomic Symptom Score-31 (COMPASS-31)
Percentage of participants who achieved ≥85% prescribed minutes (714 of 840 min)
Show 1 moreShow less
Percentage of patients that completed ≥70% of scheduled autonomic measurements
Arms and interventions
Sham-AMSham comparator
Participants will use the sham-device for 1 hr/day at 7:00 AM.
Sham-PMSham comparator
Participants will use the sham-device for 1 hr/day at 7:00 PM.
Active-AMExperimental
Participants will use the active AVNT device for 1 hr/day at 7:00 AM.
Active-PMExperimental
Participants will use the active AVNT device for 1 hr/day at 7:00 PM.
Devices: Auricular Vagal Neuromodulation Therapy (AVNT™), Sham-device
Sites
1 site in 1 country
- NYU Langone HealthNew York, New York, United States